Know Cancer

or
forgot password

Evaluation of Renal Masses Using Ultrasound Intravenous Microbubble Contrast


Phase 2
21 Years
N/A
Not Enrolling
Both
Renal Cancer, Kidney Cancer

Thank you

Trial Information

Evaluation of Renal Masses Using Ultrasound Intravenous Microbubble Contrast


Inclusion Criteria:



- Any adult patient who is planned or scheduled for surgical excision or biopsy of a
solid or complex cystic renal mass would be eligible for the study

- Histology of the renal mass must be unknown at the time of enrollment

- Patients who have renal masses that are evident on conventional US imaging

- Patients will have a correlative abdominal CT and/or MRI

Exclusion Criteria:

- Patients with any history of cardiac shunts.

- Patients with history of pulmonary hypertension or unstable cardiopulmonary
conditions, including patients on mechanical ventilation.

- Patients without peripheral IV access

- Pregnant patients and children

- Patients with any known contrast allergies, allergy to perflutren, or any components
of Definity or microbubble contrast

- Patients who have renal masses that are not evident on conventional US imaging

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

To determine the accuracy of contrast enhanced ultrasound of renal masses to predict benign vs. malignant histology

Outcome Time Frame:

conclusion of study

Safety Issue:

No

Principal Investigator

Scott Gerst, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Food and Drug Administration

Study ID:

07-165

NCT ID:

NCT00671411

Start Date:

March 2008

Completion Date:

November 2011

Related Keywords:

  • Renal Cancer
  • Kidney Cancer
  • Ultrasound
  • 07-165
  • Carcinoma, Renal Cell
  • Kidney Neoplasms

Name

Location

Memorial Sloan-Kettering Cancer CenterNew York, New York  10021